<DOC>
	<DOC>NCT02376049</DOC>
	<brief_summary>An Explorative Clinical Trial to Evaluate an Intra Patient Comparison Design of Topical Agents in Adults with Mild to Moderate Atopic Dermatitis.</brief_summary>
	<brief_title>A Clinical Trial to Compare Topical Agents in Adults With Mild to Moderate Atopic Dermatitis (AD)</brief_title>
	<detailed_description>Multi-center, prospective, randomized, vehicle-controlled, investigator-blinded, stable lesion design.</detailed_description>
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis, Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Betamethasone benzoate</mesh_term>
	<mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
	<mesh_term>Pimecrolimus</mesh_term>
	<mesh_term>Betamethasone</mesh_term>
	<mesh_term>Betamethasone Valerate</mesh_term>
	<mesh_term>Clobetasol</mesh_term>
	<mesh_term>Betamethasone sodium phosphate</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<criteria>Subject with mild to moderate AD Four comparable TAs TSS of at least 5 on all TAs Difference in TSS not greater than 2 between the TAs Sign score erythema â‰¥ 2 between the TAs TAs should be at least 2 cm apart Investigator's opinion Fitzpatrick skin type &gt;5 Topical (i.e. on the TAs) treatment with prohibited medications Systemic treatment with prohibited medications Phototherapy within prohibited timeframe Use of emollients within prohibited timeframe</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Atopic Dermatitis</keyword>
	<keyword>Eczema</keyword>
	<keyword>AD</keyword>
</DOC>